Company intelligence / Profile preview

Biospectal

Lausanne, VD, Switzerlandbiospectal.com ↗

Ownership: Private
Employees: ~10
Development stage: Commercial

Overview

Biospectal’s OptiBP™ app enables instant, accurate remote blood pressure monitoring using a smartphone camera. The technology has been validated against reference auscultatory measurements and fulfills AAMI/ESH/ISO universal standards. It is CE marked and has won industry recognition including Fast Company’s Next Big Things in Tech award. Clinical results demonstrate equivalence to traditional cuff-based methods for systolic and diastolic blood pressure measurement.

Therapeutic areas: Cardiovascular
Modalities: DeviceNon-pharmacological therapyDigital health software platform
Industry: Physiological Monitoring

Partnerships

SeedLink (lead investor)LabCorpAthensmedPrivilege Ventures; no major pharma partnerships disclosed but investors include healthcare organizations like LabCorp.

Beyond the preview

Go deeper on Biospectal.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biospectal.

Explore the full profile